目的观察吉西他滨（GEM）为主方案联合重组人血管内皮抑素（恩度）治疗晚期胆系肿瘤（biliary tractcancer，BTC）的疗效及安全性，探讨恩度在BTC治疗中的作用。方法选取2005-01-01—2015-04—01解放军第八一医院全军肿瘤中心收治的ⅣB...目的观察吉西他滨（GEM）为主方案联合重组人血管内皮抑素（恩度）治疗晚期胆系肿瘤（biliary tractcancer，BTC）的疗效及安全性，探讨恩度在BTC治疗中的作用。方法选取2005-01-01—2015-04—01解放军第八一医院全军肿瘤中心收治的ⅣB期BTC患者109例为研究对象，分为恩度联合组（n=25）和单纯化疗组（n=84）。恩度联合组：吉西他滨和顺铂（GP，n=1）或奥沙利铂（GEMOX，n=22）或卡培他滨（GX，n=2）联合恩度。吉西他滨1000mg／m2，静脉滴入，d1、d8；顺铂20mg，d2～d6。或者奥沙利铂100mg／m2，静脉滴入，d2。或者卡培他滨1000mg／m2，口服，2次／d，d1～d14。恩度15mg，静脉滴入，d1～d14，3周为1个周期。单纯化疗组：仅给予GP（n=9）或GEMOX（n=40）或GX（n=35）方案化疗，剂量与使用方法同联合组。2个周期后按照RECIST1．0标准、NCI—CTC3．0版分别评价疗效与不良反应。用Kaplan-Meier法绘制生存曲线，Log—Rank检验进行两组比较。结果恩度联合组25例患者，CR1例，PR8例，SD12例，PD4例，有效率（resonse rate，RR）36．0％，疾病控制率（disease control rate，DCR）84．0％；中位无进展生存时间（progression—free survival，PFS）为5．8个月，中位总生存时间（overall survival，OS）为12．3个月；生活质量（quality of life，QOL）改善及稳定率为88％。单纯化疗组84例患者，CR1例，PR10例，SD42例，PD31例，RR为13．1％，DCR为63．1％；中位PFS为3．8个月，中位OS为8．0个月；QOL改善及稳定率80．9％。两组RR和DCR比较差异有统计学意义，P〈0．05；两组中位PFS和中位OS比较差异有统计学意义，P〈0．05。两组不良反应最常见为骨髓抑制，其他不良反应包括恶心、呕吐、外周神经炎、皮疹、发热和手足综合征等，以1～2级为主，两组比较差异无统计学意义，P〉0．05。化疗联合恩度组仅2例出现心电图T波改变，展开更多
目的:研究放疗联合周剂量重组人血管内皮抑素(recombinant human endostatin,rh-Endostatin)对肺腺癌A549裸鼠移植瘤生长的抑制作用。方法:40只裸鼠A549细胞移植瘤模型随机分成4组:空白对照组、rh-Endostatin治疗组、放射治疗组和放疗联...目的:研究放疗联合周剂量重组人血管内皮抑素(recombinant human endostatin,rh-Endostatin)对肺腺癌A549裸鼠移植瘤生长的抑制作用。方法:40只裸鼠A549细胞移植瘤模型随机分成4组:空白对照组、rh-Endostatin治疗组、放射治疗组和放疗联合rh-Endostatin治疗组,观察并绘制肿瘤生长曲线图,计算肿瘤体积抑制率;肿瘤组织行常规HE病理学检查,免疫组织化学法检测肿瘤组织中微血管内皮CD31的表达及肿瘤微血管密度(microvessel density,MVD)的变化;采用免疫组织化学及Western印迹法检测血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达;TUNEL法检测肿瘤细胞的凋亡。结果:治疗第8天起,放疗联合rh-Endostatin治疗组的肿瘤体积与对照组相比,差异有统计学意义(P<0.05)。15 d后,rh-Endostatin治疗组、放射治疗组和放疗联合rh-Endostatin治疗组小鼠的肿瘤体积的抑制率依次为68.35%、90.78%和106.56%;rh-Endostatin治疗组小鼠的MVD较放射治疗组下降明显(P<0.05);但rh-Endostatin治疗组与对照组、放疗联合rh-Endostati治疗组及放射治疗组相比,VEGF的改变差异均无统计学意义;放疗联合rh-Endostatin治疗组细胞凋亡明显。结论:放疗联合周剂量rh-Endostatin能抑制肿瘤的生长,较早诱导肿瘤退缩,可能与减少放射治疗后肿瘤血管再生及增加肿瘤细胞和内皮细胞的凋亡相关;各治疗组小鼠均未出现急性不良反应,因此该方法具有短疗程的优势,可用于临床推广。展开更多
Objective: Anti-angiogenic drugs are an emerging treatment option against malignant tumors. The aim of this study was to determine whether the addition of perioperative rh-endostatin to chemotherapy could improve the ...Objective: Anti-angiogenic drugs are an emerging treatment option against malignant tumors. The aim of this study was to determine whether the addition of perioperative rh-endostatin to chemotherapy could improve the probability of distant metastasis-free survival(DMFS) and overall survival(OS) in patients newly diagnosed with non-metastatic conventional osteosarcoma.Methods: This was a controlled non-randomized clinical study that included 388 patients without clinically detectable metastatic disease enrolled from January 2008 to April 2012. The control treatment group had 272 patients; 180 were male and 92, female,with a median age of 17 years. The treatment group had 58 patients; 36 were male and 22, female, with a median age of 16 years.The control group received preoperative chemotherapy followed by surgery and postoperative chemotherapy. The treatment group received 4 cycles of rh-endostatin perioperatively in addition to chemotherapy as per the control group. Patients were followed up from 6-101 months with a median follow-up period of 50.2 months.Results: The 5-year DMFS of the control group(61%) was significantly lower than that of the rh-endostatin group(79%)(P = 0.013). The 5-year OS of the control group(74%) was significantly lower than that of the rh-endostatin treatment group(87%)(P = 0.029). No difference in adverse drug reactions was found between these 2 groups.Conclusions: The addition of perioperative rh-endostatin to chemotherapy could significantly improve the DMFS and OS of patients with non-metastatic osteosarcoma.展开更多
文摘目的观察吉西他滨（GEM）为主方案联合重组人血管内皮抑素（恩度）治疗晚期胆系肿瘤（biliary tractcancer，BTC）的疗效及安全性，探讨恩度在BTC治疗中的作用。方法选取2005-01-01—2015-04—01解放军第八一医院全军肿瘤中心收治的ⅣB期BTC患者109例为研究对象，分为恩度联合组（n=25）和单纯化疗组（n=84）。恩度联合组：吉西他滨和顺铂（GP，n=1）或奥沙利铂（GEMOX，n=22）或卡培他滨（GX，n=2）联合恩度。吉西他滨1000mg／m2，静脉滴入，d1、d8；顺铂20mg，d2～d6。或者奥沙利铂100mg／m2，静脉滴入，d2。或者卡培他滨1000mg／m2，口服，2次／d，d1～d14。恩度15mg，静脉滴入，d1～d14，3周为1个周期。单纯化疗组：仅给予GP（n=9）或GEMOX（n=40）或GX（n=35）方案化疗，剂量与使用方法同联合组。2个周期后按照RECIST1．0标准、NCI—CTC3．0版分别评价疗效与不良反应。用Kaplan-Meier法绘制生存曲线，Log—Rank检验进行两组比较。结果恩度联合组25例患者，CR1例，PR8例，SD12例，PD4例，有效率（resonse rate，RR）36．0％，疾病控制率（disease control rate，DCR）84．0％；中位无进展生存时间（progression—free survival，PFS）为5．8个月，中位总生存时间（overall survival，OS）为12．3个月；生活质量（quality of life，QOL）改善及稳定率为88％。单纯化疗组84例患者，CR1例，PR10例，SD42例，PD31例，RR为13．1％，DCR为63．1％；中位PFS为3．8个月，中位OS为8．0个月；QOL改善及稳定率80．9％。两组RR和DCR比较差异有统计学意义，P〈0．05；两组中位PFS和中位OS比较差异有统计学意义，P〈0．05。两组不良反应最常见为骨髓抑制，其他不良反应包括恶心、呕吐、外周神经炎、皮疹、发热和手足综合征等，以1～2级为主，两组比较差异无统计学意义，P〉0．05。化疗联合恩度组仅2例出现心电图T波改变，
基金Ministry of Human Resources and Social Security of the People's Republic of China (MOHRSS) (Grant No. 2017199)
文摘Objective: Anti-angiogenic drugs are an emerging treatment option against malignant tumors. The aim of this study was to determine whether the addition of perioperative rh-endostatin to chemotherapy could improve the probability of distant metastasis-free survival(DMFS) and overall survival(OS) in patients newly diagnosed with non-metastatic conventional osteosarcoma.Methods: This was a controlled non-randomized clinical study that included 388 patients without clinically detectable metastatic disease enrolled from January 2008 to April 2012. The control treatment group had 272 patients; 180 were male and 92, female,with a median age of 17 years. The treatment group had 58 patients; 36 were male and 22, female, with a median age of 16 years.The control group received preoperative chemotherapy followed by surgery and postoperative chemotherapy. The treatment group received 4 cycles of rh-endostatin perioperatively in addition to chemotherapy as per the control group. Patients were followed up from 6-101 months with a median follow-up period of 50.2 months.Results: The 5-year DMFS of the control group(61%) was significantly lower than that of the rh-endostatin group(79%)(P = 0.013). The 5-year OS of the control group(74%) was significantly lower than that of the rh-endostatin treatment group(87%)(P = 0.029). No difference in adverse drug reactions was found between these 2 groups.Conclusions: The addition of perioperative rh-endostatin to chemotherapy could significantly improve the DMFS and OS of patients with non-metastatic osteosarcoma.
